Alignment Healthcare's stock is under significant pressure after its largest Medicare Advantage contract in California was downgraded from 4.0 to 3.5 stars. This downgrade means the company will lose valuable bonus payments, directly impacting its financial performance and leading to a sharp decline in share price.
Alignment Healthcare (ALHC) experienced a significant setback with the Centers for Medicare & Medicaid Services' (CMS) 2027 Medicare Advantage Star Ratings. While most of its contracts maintained high ratings, its crucial California H3815 HMO contract, which accounts for over 75% of its health plan members, was downgraded from 4.0 to 3.5 stars. This downgrade is critical because Medicare Advantage contracts must maintain at least a 4-star rating to qualify for valuable bonus payments, directly impacting ALHC's revenue and profitability. The company disputes the rating and plans to pursue administrative remedies, but the immediate short-term implication is a substantial negative impact on its stock price, as evidenced by the 22.73% premarket drop and new 52-week low. This event highlights the significant regulatory risk and dependence on CMS ratings for Medicare Advantage providers.